Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era

Published:2017-09-29 Issue:1 Volume:183 Page:149-152
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Thanarajasingam Gita¹^ORCID,Maurer Matthew J.²^ORCID,Farooq Umar³^ORCID,Johnston Patrick B.¹,Thompson Carrie A.¹,Bennani Nabila N.¹,Ansell Stephen M.¹,Porrata Luis F.¹,Macon William R.⁴,Syrbu Sergei I.⁵,Cerhan James R.²,Habermann Thomas M.¹,Link Brian K.³,Witzig Thomas E.¹,Nowakowski Grzegorz S.¹

Affiliation:

1. Division of Hematology; Mayo Clinic; Rochester MN USA

2. Department of Health Sciences Research; Mayo Clinic; Rochester MN USA

3. Division of Hematology, Oncology and Blood & Marrow Transplantation; University of Iowa; Iowa City IA USA

4. Department of Laboratory Medicine and Pathology; Mayo Clinic; Rochester MN USA

5. Department of Pathology; University of Iowa; Iowa City IA USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14922/fullpdf

Reference10 articles.

1. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse;Bernard;Blood,2015

2. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the Southwest Oncology Group;Bernstein;Journal of Clinical Oncology,2009

3. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL);Boehme;Annals of Oncology,2007

4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

5. Prevention of CNS relapse in diffuse large B-cell lymphoma;Kridel;The Lancet. Oncology,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001;Blood;2024-02-01

2. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2022-10

3. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study;The Lancet;2020-09

4. CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies;Blood Cancer Journal;2018-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3